Trial Profile
Phase II trial of nivolumab following radiation therapy to bone metastases in patients with non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms RT-Nivo NSCLC phase II
- 30 Jan 2021 Status changed from recruiting to discontinued.
- 30 Jul 2017 Status changed from not yet recruiting to recruiting.
- 06 Feb 2017 New trial record